Faculty

Institution

Unit

Venue

Aman U. Buzdar

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

NoneAman U. Buzdar is currently serving as a Division Of Medical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Aman U. Buzdar

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

breast cancer oncology cancer care radiation oncology cancer research medicine pharmacology cancer treatment breast oncology surgical oncology jama oncology metastasis gynecologic oncology cancer letter pharmacotherapy cancer discovery medicinal research gynecologic cancers pathology clinical trials clinical research cancer management tumor biology molecular cancer cancer cells cancer biology future medicinal chemistry metastatic breast cancer cancer imaging oncogenes anti-cancer agents neoadjuvant chemotherapy breast surgery surgical pathology thoracic oncology advanced breast cancer medical mycology cancer risk endocrine-related cancers clinical radiation oncology endocrine oncology prognosis therapeutic efficacy operable breast cancer radiation therapy tumor targeting breast cancer patients treatment and prevention clinical evidence breast carcinoma lymphoid neoplasia postmenopausal women adjuvant chemotherapy cancer genomics metronomic chemotherapy combination chemotherapy primary chemotherapy cancer prevention disease progression breast imaging prognostic evaluation cancer genetics malignant disease cohort studies clinical mycology phase ii study drug trials drug targeting hormonal receptor neoadjuvant therapy inflammatory breast cancer induction chemotherapy treatment development aromatase inhibitors preoperative chemotherapy therapy resistance pharmacognosy carcinogenesis therapeutic targets individualized medicine translational research cancer immunotherapy cell biology drug metabolism drug discovery health sciences translational medicine medicinal chemistry cellular therapy prostate cancer urology endocrinology ovarian cancer tumor microenvironment personalized medicine alternative medicine applied pharmacology molecular medicine natural product communication brain tumor research gynecology experimental medicine pharmacological research leukemia

Notable Scholarly Works

Notable Federal Grants

Collaborators

Early On-Treatment (On-Rx) Tumor Volume Reduction (Tvr) to Predict Response to the Keynote-522 (Kn-522) Regimen in Early Stage Triple Negative Breast Cancer (Tnbc).. Journal of Clinical Oncology (2025)

tumor volume reductionradiologyearly on-treatmentradiation oncologycancer discoverycancer imagingbreast canceroncologycancer treatmentjama oncologybreast oncology

Abstract Her2-01: Her2-01 Clinical and Molecular Characteristics of Her2-Low/Zero Early Stage Triple-Negative Breast Cancer. Cancer Research (2023)

her2-01 clinicalmolecular cancerbreast oncologybreast canceroncologyoncogenescancer cellsmolecular characteristicspathologytumor biologycell biology

Investigating the Disparate Enrollment of Older Adults on Phase I Clinical Trials: Evolving Participation Patterns of Patients 65 Years and Older W Advanced Cancer on Phase I Trials.. Journal of Clinical Oncology (2020)

Ishwaria Mohan SubbiahAman BuzdarEcaterina Elena Ileana DumbravaSiqing FuFilip JankuDaniel D. KarpAung NaingShubham PantJordi RodonApostolia Maria TsimberidouTimothy A YapVivek SubbiahFunda Meric-BernstamDavid S. Hong

participation patternsolder adultsclinical trialsoncologyclinical researchdisparate enrollmenthealth sciencescancer disparities

Pharmacogenomics of Aromatase Inhibitors in Postmenopausal Breast Cancer and Additional Mechanisms of Anastrozole Action. JCI Insight (2020)

Junmei CairnsJames N. IngleTanda M. DudenkovKrishna R. KalariErin E. CarlsonJie NaAman U. BuzdarMark E. RobsonMatthew J. EllisPaul E. GossLois E. ShepherdBarbara GoodnatureMatthew P. GoetzRichard M. WeinshilboumHu LiMehrab Ghanat BariLiewei Wang

pharmacologypharmacogenomicsaromatase inhibitorspostmenopausal breast cancerbreast canceranastrozole action

Single-Nucleotide Polymorphism Biomarkers of Adjuvant Anastrozole-Induced Estrogen Suppression in Early Breast Cancer. Pharmacogenetics and Genomics (2020)

James N. IngleKrishna R. KalariPoulami BarmanLois E. ShepherdMatthew J. EllisPaul E. GossAman U. BuzdarMark E. RobsonJunmei CairnsErin E. CarlsonAbraham Eyman CaseyTanya L. HoskinBarbara A. GoodnatureTufia C. HaddadMatthew P. GoetzRichard M. WeinshilboumLiewei Wang

medicinal chemistrypharmacologybiomarkersgenomic medicinepharmacogenomicsgeneticspharmacotherapymolecular pharmacologycancer genomicssingle-nucleotide polymorphism biomarkersbreast canceroncologymedicinal researchearly breast cancermedical geneticshealth sciencespharmacological researchbreast oncology

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between Slc 38A7 and Alppl 2. Clinical Pharmacology & Therapeutics (2019)

Tanda M. DudenkovDuan LiuJunmei CairnsSandhya DevarajanYongxian ZhuangJames N. IngleAman U. BuzdarMark E. RobsonMichiaki KuboAnthony BatzlerPoulami BarmanGregory D. JenkinsErin E. CarlsonMatthew P. GoetzDonald W. NorthfeltAlvaro Moreno‐AspitiaZeruesenay DestaJoel M. ReidKrishna R. KalariLiewei WangRichard M. Weinshilboum

medicinal chemistrygenomicsmedicinepharmacologypharmacokineticsclinical chemistryclinical researchfunctional epistatic interactionhealth sciences

Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer. Holland‐Frei Cancer Medicine (2019)

radiation oncologyendocrinologygynecologic oncologybreast canceroncologycancer lettergynecology

A Phase II Study of Tipifarnib and Gemcitabine in Metastatic Breast Cancer. Investigational New Drugs (2018)

tumor targetingmetastasispharmacologyradiation oncologymolecular cancercancer discoveryanti-cancer agentsphase ii studybreast canceroncologyoncogenescancer cellscancer treatmentmetastatic breast cancerbreast oncology

Disease-Free and Overall Survival Among Patients With Operable Her2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology (2018)

medicinebreast surgerycancer careoverall survivalradiation oncologysurgical oncologycancer discoverybreast canceroncologyconcurrent chemotherapycancer treatmentbreast oncology

Abstract Pd1-04: Csmd1 Snps Selectively Affect Anastrozole Response in Postmenopausal Breast Cancer Patients. Cancer Research (2017)

J CairnsJ IngleT DudenkovK KalariA BuzdarM KuboM RobsonM EllisP GossL ShepherdM GoetzR WeinshilboumL Wang

endocrine-related cancerspharmacologycancer geneticscsmd1 snpsradiation oncologycancer researchmolecular cancergynecologic oncologycancer discoverycancer genomicscsmd1 snpbreast canceroncologyoncogenesmedicinal researchestrogen receptorcancer riskbreast oncology

1
2
3
4
5
62
10 / page

Aman U. Buzdar

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

NoneAman U. Buzdar is currently serving as a Division Of Medical Oncology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Aman U. Buzdar

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

tumor volume reductionradiologyearly on-treatmentradiation oncologycancer discoverycancer imagingbreast canceroncologycancer treatmentjama oncologybreast oncology

Abstract Her2-01: Her2-01 Clinical and Molecular Characteristics of Her2-Low/Zero Early Stage Triple-Negative Breast Cancer. Cancer Research (2023)

her2-01 clinicalmolecular cancerbreast oncologybreast canceroncologyoncogenescancer cellsmolecular characteristicspathologytumor biologycell biology

participation patternsolder adultsclinical trialsoncologyclinical researchdisparate enrollmenthealth sciencescancer disparities

Pharmacogenomics of Aromatase Inhibitors in Postmenopausal Breast Cancer and Additional Mechanisms of Anastrozole Action. JCI Insight (2020)

pharmacologypharmacogenomicsaromatase inhibitorspostmenopausal breast cancerbreast canceranastrozole action

Single-Nucleotide Polymorphism Biomarkers of Adjuvant Anastrozole-Induced Estrogen Suppression in Early Breast Cancer. Pharmacogenetics and Genomics (2020)

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between Slc 38A7 and Alppl 2. Clinical Pharmacology & Therapeutics (2019)

medicinal chemistrygenomicsmedicinepharmacologypharmacokineticsclinical chemistryclinical researchfunctional epistatic interactionhealth sciences

Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer. Holland‐Frei Cancer Medicine (2019)

radiation oncologyendocrinologygynecologic oncologybreast canceroncologycancer lettergynecology

A Phase II Study of Tipifarnib and Gemcitabine in Metastatic Breast Cancer. Investigational New Drugs (2018)

Disease-Free and Overall Survival Among Patients With Operable Her2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology (2018)

medicinebreast surgerycancer careoverall survivalradiation oncologysurgical oncologycancer discoverybreast canceroncologyconcurrent chemotherapycancer treatmentbreast oncology

Abstract Pd1-04: Csmd1 Snps Selectively Affect Anastrozole Response in Postmenopausal Breast Cancer Patients. Cancer Research (2017)

J CairnsJ IngleT DudenkovK KalariA BuzdarM KuboM RobsonM EllisP GossL ShepherdM GoetzR WeinshilboumL Wang

1
2
3
4
5
62
10 / page